Long Non-coding RNAs in Gammaherpesvirus Infections: Their Roles in Tumorigenic Mechanisms

Wen Liu¹, Yan Zhang¹,² and Bing Luo¹*

¹ Department of Pathogenic Biology, School of Basic Medicine, Qingdao University, Qingdao, China, ² Department of Clinical Laboratory, Zibo Central Hospital, Zibo, China

Long non-coding RNAs (lncRNAs) regulate gene expression at the epigenetic, transcriptional, or posttranscriptional level by interacting with protein, DNA, and RNA. Emerging evidence suggests that various lncRNAs are abnormally expressed and play indispensable roles in virus-triggered cancers. Besides, a growing number of studies have shown that virus-encoded lncRNAs participate in tumorigenesis. However, the functions of most lncRNAs in tumors caused by oncogenic viruses and their underlying mechanisms remain largely unknown. In this review, we summarize current findings regarding lncRNAs involved in cancers caused by Epstein–Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV). Additionally, we discuss the contribution of lncRNAs to tumor occurrence, development, invasion, and metastasis; the roles of lncRNAs in key signaling pathways and their potential as biomarkers and therapeutic targets for tumor diagnostics and treatment.

Keywords: gammaherpesvirus, Epstein–Barr virus, KSHV, lncRNA, tumorigenesis

INTRODUCTION

Infectious diseases are an important cause of human cancer, of which approximately 15–20% are virus-triggered. The viruses responsible are thus denoted as oncoviruses or oncogenic viruses. Studies of oncogenic viruses have proved invaluable in understanding the mechanisms of cancer occurrence and progression. Several cancer biomarkers have been discovered and have guided the exploitation of new tumor treatment strategies. Human oncogenic viruses include DNA viruses:

Abbreviations: EBV, Epstein–Barr virus; KSHV, Kaposi's sarcoma-associated herpesvirus; NPC, nasopharyngeal carcinoma; GC, gastric carcinoma; KS: Kaposi's sarcoma; PEL, primary effusion lymphoma; MCD, multicentric Castleman's disease; LMP, latent membrane protein; EBNA, Epstein–Barr nuclear antigen; LANA, latency-associated nuclear antigen; vFLIP, viral homolog for the cellular FAS-associated death domain-like interleukin-1β converting enzyme (FLICE)-like inhibitory protein; ceRNA, competitive endogenous RNA; BARTs, BamHI-A rightward transcripts; Pol II, RNA polymerase II; vCyc, viral homolog for a cellular D cyclin; PAN RNA, polyadenylated nuclear RNA; PRC2, polycomb repressor complex 2; ALT, antisense-to-latency transcript; SNHG, small nucleolar RNA host gene; vIRF1, viral interferon regulatory factor 1; HMGB2, high-mobility group box 2; MALAT1, metastasis-related lung adenocarcinoma transcript 1; EBVaGC, EBV-associated gastric cancer; NEAT1, nuclear paraspeckle assembly transcript 1; HOTAIR, HOX transcript antisense intergenic RNA; EMT, epithelial–mesenchymal transition; VEGFA, vascular endothelial growth factor A.
high-risk human papillomavirus (HPV), Merkel cell polyomavirus (MCPyV), hepatitis B virus (HBV), Epstein–Barr virus (EBV), and Kaposi’s sarcoma-associated herpesvirus (KSHV); RNA viruses: hepatitis C virus (HCV) and human T-cell leukemia virus type 1 (HTLV-1); as well as some serotypes of human adenoviruses, even though they have not been linked to any human cancer (Grassmann et al., 2008; Schafer et al., 2015; Krum and You, 2018). Among them, EBV and KSHV are both large double-stranded DNA (dsDNA) viruses, and they can establish long-term or even lifelong chronic infections that show no obvious post-infection symptoms. These two viruses share many features that can initiate many lymphoproliferative diseases and multitudinous malignancies (Krum and You, 2018). EBV is the first human tumor virus infecting more than 90% of the world’s population. A lifelong latent EBV infection is associated with multiple human cancers, including Burkitt’s lymphoma (BL), Hodgkin’s lymphoma (HL), natural killer (NK)/T cell lymphoma, nasopharyngeal carcinoma (NPC), and some gastric carcinomas (GCs) (Saha et al., 2010; Young et al., 2016). KSHV (also known as human herpesvirus 8), which also belongs to the gammaherpesvirus subfamily, mainly causes Kaposi’s sarcoma (KS) (da Silva and de Oliveira, 2011). KS is the most common AIDS-associated malignancy (Ganem, 2010). However, the underlying mechanisms of these viruses in promoting tumorigenesis and development remain poorly understood.

As large dsDNA gammaherpesviruses, both EBV and KSHV should evade the innate immune response mainly by restricting the expression of viral genes to establish a stable infection in the host (Jangra et al., 2019). EBV and KSHV can alter the expression of viral genes via genetic regulation directly, encoding various viral microRNAs (miRNAs), or changing the expression of function of host genes (Lung et al., 2009; Mansouri et al., 2014; Zhang Y. et al., 2018). The expression pattern of EBV viral proteins is disease-specific and is typically identified as four latency patterns: type III, type II, type I, and type 0 latency (Young and Rickinson, 2004). EBV latency proteins, especially Epstein–Barr nuclear antigen 1 (EBNA1) and latent membrane proteins (LMP-1 and LMP-2A), have been well studied and are considered cell-transforming and carcinogenesis-promoting oncoproteins (Shair and Raab-Traub, 2012; Frappier, 2015; Wang L.W. et al., 2017). Recently, EBV non-coding RNAs (ncRNAs), RPMSI, EBV miRNAs, and EBER1/2 have gained emphasis. They were demonstrated as significantly affecting oncogenesis by interfering with the cell cycle, host immune responses, and apoptosis (Marquitz et al., 2015; Albanese et al., 2017; Skinner et al., 2017; Zhang J. et al., 2018; Liu et al., 2020). Likewise, KSHV employs oncoproteins and ncRNAs such as latency-associated nuclear antigen (LANA), viral FLICE inhibitory protein (vFLIP), and KSHV-encoded miRNAs to achieve latent infection and tumorigenic processes (Samols et al., 2007; Ballon et al., 2011; Yang et al., 2014; Wei et al., 2016; Hussein et al., 2019). Thus, the use of ncRNAs to regulate the biological process of host cells is an important strategy in virus infection to avoid eliciting immune clearance by the host (Ungerleider et al., 2018).

Only a very small part of the mammalian genome encodes protein-coding genes, with most of the genome transcribed as ncRNAs (Holoch and Moazed, 2015). With the development of sequencing technology and bioinformatics in the past two decades, we have a deeper understanding of the ncRNA richness and their possible roles in human cells – we now realize that these non-coding transcripts are not transcriptional noise, but serve important biological functions. NcRNAs are roughly divided into three types: miRNAs, long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) (Chen et al., 2016). Current studies have revealed multiple functions of lncRNAs in various cell processes by regulating gene expression, including cell migration, proliferation, cell cycle, apoptosis, and autophagy (Kung et al., 2013; Huarte, 2015). The abnormal expression of lncRNAs, which involves various important pathways, is closely related to the occurrence and development of tumors (Huarte, 2015; Bullard et al., 2018; Castro-Oropeza et al., 2018; Lin, 2020). LncRNAs encoded by oncogenic viruses have been considered important cofactors that participate in tumorigenesis (Zhang et al., 2016; Liu and Ding, 2017). Due to their close relationship with tumor initiation, invasion, and metastasis, and drug sensitivity and resistance, these lncRNAs can serve as novel therapeutic targets and treatment tools for viral tumors. Recent studies have attempted to clarify the molecular mechanism of these RNAs, thereby providing new insight into their functions and applications (Huarte and Rinn, 2010). Here, we focus on the recent understanding of lncRNAs involved in EBV- and KSHV-associated tumors, especially on their roles in the establishment of latent infection and oncogenesis.

**THE MOLECULAR FUNCTION OF LONG NON-CODING RNAs**

As important regulatory RNAs in tumor biology, lncRNAs are involved in multiple major biological functions, for instance, cell proliferation, invasion, metastasis, and apoptosis (Lin, 2020; Zhou et al., 2020). Based on their genomic location, lncRNAs are mainly categorized into five types: antisense, bidirectional, intronic, enhancer-associated, and intergenic (Robinson et al., 2020). Mechanistically, lncRNAs function at all epigenetic, transcriptional, and posttranscriptional levels with diverse mechanisms. LncRNAs regulate histone modification and DNA methylation in pre-transcriptional regulation (Schmitz et al., 2016). By directly binding to transcription factors or chromatin modifiers, lncRNAs act as a scaffold to direct them to precise locations in the genome by *cis* or *trans* regulation (Wilusz et al., 2009). Besides, lncRNAs regulate mRNA transcripts by affecting the stability, changing the splicing activity, editing modifications, or regulating RNA subcellular localization. It can act as a competitive endogenous RNA (ceRNA) or “sponge” for miRNAs, indirectly de-repressing the expression of the mRNA that would be targeted by these miRNAs (Huarte, 2015; Li T. et al., 2016; Yan et al., 2019; Robinson et al., 2020). Furthermore, cellular lncRNAs can also be targeted by miRNAs (Sethuraman et al., 2018). However, further evidence with detailed regulatory mechanism is required to support this view.
VIRAL-ENCODED LONG NON-CODING RNAs OF EPSTEIN–BARR VIRUS AND KAPOSI’S SARCOMA HERPESVIRUS

Viral-encoded lncRNAs are expected to play an important role in maintaining stable virus infection and promoting tumorigenesis and tumor progression (Zheng, 2010; Li Z. et al., 2016). Currently, a small number of known EBV- and KSHV-encoded lncRNAs exist, and their biological significance remains to be determined. However, with the advancement of technology and more in-depth analysis of the viral genome, we have gradually discovered these virus-related ncRNAs and began studying their functions in viral-associated malignancies. EBV- and KSHV-encoded viral genes are mostly associated with establishing stable latent infections, while lncRNAs, as important ncRNAs, are certainly involved in latency regulation. Here, we describe several EBV- and KSHV-encoded lncRNAs that are better-characterized.

Epstein–Barr Virus-Encoded Long Non-coding RNAs

Epstein–Barr virus miRNAs and lncRNAs can target each other and share several common signaling pathways, forming an interconnected, complex molecular regulatory network. EBV also encodes its own viral lncRNAs such as EBV bamHI-A rightward transcripts (BARTs) expressed in all EBV-associated diseases. BARTs contain several forms of splicing in EBV-infected cells. A study detected BARF0, RPM51, RPM51A, and A73 genes as four major splicing forms encoded by BART; but no endogenous BART-translated protein was detected (Yamamoto and Iwatsuki, 2012). Full-length BART RNA reportedly functions as lncRNA in the nucleus of GC cells, which induces transcriptional reprogramming associated with latent EBV infection. In the report, eight genes were strongly downregulated by BART lncRNA, including RASIP1, SLC7A11, PGC, CDH11, RNF144B, ATF5, VEGFA, and ITGA6 (Marquitz et al., 2015). NPC is the most common malignant tumor of head and neck squamous cell carcinoma. It occurs in southern China and Southeast Asia and is closely related to EBV infection. More than 90% of non-differentiated NPC cases are EBV-positive. High levels of BART expression have also been reported in NPC. The regulation of BARTs is postulated to be related to EBV pathogenesis in NPC (Verhoeven et al., 2016), and BART lncRNAs are involved in the epigenetic regulation of host gene expression in NPC. BART lncRNA is located in the nucleus and regulates the expression of interferon beta 1 (IFNB1) and chemokine (C-X-C motif) ligand 8 (CXCR8) by inhibiting polymerase II (Pol II) transcription (Verhoeven et al., 2019). Together, BART lncRNAs participate in transcription reprogramming of host gene expression in both Epstein–Barr virus-associated gastric carcinoma (EBVaGC) and NPC. Nevertheless, most of the target genes that interact with BART lncRNAs remain unknown.

Epstein–Barr virus-encoded BHLF1 is an early lytic gene that is expressed at a low level during the initiation of latency but at a high level during reactivation. BHLF1 encodes several RNAs and performs non-coding functions (lncRNA and circRNA) during the viral replicative cycle (Ungerleider et al., 2019; Yetming et al., 2020). BHLF1 lncRNA acts as the essential promoter of the origin of lytic replication (OriLyt) to promote DNA replication. Efficient protein expression of BHLF1 requires the EBV posttranscriptional regulator protein SM, which is expressed only in the replicative cycle. Therefore, BHLF1 lncRNA may have an important role in the lytic cycle. Meanwhile, Yetming et al. (2020) indicated that BHLF1 lncRNA also contributes to viral latency.

Kaposi’s Sarcoma Herpesvirus-Encoded Long Non-coding RNAs

Kaposi’s sarcoma herpesvirus is closely associated with the occurrence of various malignant tumors. Among them, KS is a common tumor in patients with AIDS, which causes death (Chang et al., 1994). KSHV is a dsDNA virus consisting of ~165-kb genome that encodes approximately 90 viral proteins and many ncRNAs (Campbell et al., 2020). To prevent elimination by the host immune response, KSHV establishes a latent infection. During latency, KSHV restricts viral gene expression to a few latent proteins and an array of viral microRNAs and lncRNAs (Samols et al., 2007; Schifano et al., 2017). Three main latency genes are commonly expressed in KS and PEL: LANA, vFLIP, and the viral homolog for a cellular D cyclin (vCyc). As summarized by Hussein et al. (2019), the KSHV genome also encodes 25 mature miRNAs.

Approximately 16 potential KSHV lncRNAs have been reported as present in infected cells (Schifano et al., 2017). To date, polyadenylated nuclear RNA (PAN RNA) is the most important and well-characterized KSHV lncRNA, which was first described in 1996 (Sun et al., 1996; Zhong et al., 1996). PAN RNA is a multifunctional regulatory transcript and plays important roles in reactivation and replication, viral gene expression, and immune modulation by interacting with viral and cellular proteins and DNA (Figure 1; Borah et al., 2011; Rossetto and Pari, 2011, 2014; Rossetto et al., 2013; Campbell et al., 2014b; Sztuba-Solinska et al., 2017). PAN RNA is abundantly expressed throughout lytic replication and plays a vital role in viral replication. Besides interacting with cellular proteins, it can also interact with viral proteins (Rossetto and Pari, 2014). The significant and diverse functions of PAN RNA in KSHV lytic replication have been well described (Campbell and Izumiya, 2020).

Polyadenylated nuclear RNA has been implicated in transcription and chromatin remodeling, and LANA is a nuclear protein expressed during latent KSHV infection that interacts with PAN RNA (Song et al., 2001). By interacting with PAN RNA, LANA dissociates from the viral episomes, facilitating lytic reactivation (Campbell et al., 2014a). Recent reports have shown that PAN RNA plays significant roles such as binding to the transcription factor IRF4 to inhibit transcription of downstream genes, interacting with the lysine demethylase JMJD3 complex to regulate gene expression by removing repressive H3K27Me, and binding to the lysine methylase EZH2 [a histone methyltransferase subunit of the epigenetic regulator polycomb repressor complex 2, PRC2,
which suppresses gene expression by adding three methyl groups to lysine 27 of histone 3 (H3K27) to regulate gene expression via repressing methylation (Rossetto and Pari, 2012, 2014; Kim and Roberts, 2016). KSHV can also induce EZH2 expression through the expression of vFLIP and LANA to promote angiogenesis (He et al., 2012). Additionally, PAN RNA was shown to interact with histones H1 and H2A, PRC2, and KSHV open reading frames (ORFs) (26, 57, and 59). These studies suggest that PAN RNA potentially affects the expression of KSHV and cellular genes and functions in epigenetic gene regulation, similar to cellular lncRNAs.

Antisense-to-latency transcript (ALT) is a potential non-coding transcript antisense that was discovered from genome-wide tiled microarray studies. However, its role in KSHV latency and pathogenesis remains unknown (Arias et al., 2014; Schifano et al., 2017). As a potential KSHV lncRNA, the function of ALT during infection and pathogenesis remains unknown (Bullard et al., 2018). In the future, further research should be conducted to clarify the roles and molecular mechanisms of viral lncRNAs in oncogenesis and its clinical applications.

### CELLULAR LONG NON-CODING RNAs REGULATED BY EPSTEIN–BARR VIRUS AND KAPOSI’S SARCOMA HERPESVIRUS

Viral infections are reported to regulate host lncRNAs and play an important role in the occurrence and progression of viral-related tumors. EBV and KSHV deregulate host lncRNAs via direct interaction through using latency-associated proteins or through viral miRNAs to drive tumorigenesis (Table 1).

EBstein–Barr virus encodes two clusters including 44 mature miRNAs, many of which promote cancer progression by targeting host genes. However, few EBV miRNAs showed inhibition in tumor cell migration and invasion. EBV viral
miR-BART14 was found to repress the expression of lncRNA AFGL31P, which is associated with mitochondrial fusion and may trigger apoptosis via bioinformatics identification (Li C.W. et al., 2018). LOC553103 has been reported to promote epithelial–mesenchymal transition (EMT) and thereby increase the invasive and metastatic capability of NPC cells. EBV-encoded miR-BART6-3p directly targets and downregulates lncRNA LOC553103 to inhibit NPC and GC cell invasion and metastasis via the regulation of EMT-related molecular targets, such as upregulating E-cadherin and downregulating β-catenin, Snail, and N-cadherin (He et al., 2016). Besides, EBV regulates cell cycle and inhibits cell proliferation via the miR-BART6-3p/LOC553103/STMN1 axis (Wang et al., 2020).

Gallo et al. (2017) analyzed the expression of 90 lncRNAs in human EBV-transformed lymphoblastoid cell line (LCL) and peripheral blood mononuclear cells (PBMCs) and found that four lncRNAs showed higher expression in the LCL, including 7SL, H19, H19 antisense, and p53 mRNA. H19 and H19 antisense were enriched in LCL exosome cargo (Gallo et al., 2017) and may contribute to EBV-driven tumorigenesis. Reports indicate that NPC cells are ubiquitously infected with EBV. Li X.X. et al. (2018) found that 62 genes trans-regulated by lncRNAs were involved in the EBV infection pathway in NPC. Moreover, they identified eight lncRNAs dysregulated in NPC (C666-1) and GC (AGS-EBV) cells, including lncRNA-BC200, metastasis-related lung adenocarcinoma transcript 1 (MALAT1), LINC00672, LOC553103, IGFBP7-AS1, LOC100128494, LINC00982, and LINC02067. Further analysis revealed that GAS5, DLEU2, and nuclear paraspeckle assembly transcript 1 (NEAT1) were previously identified in the putative viral miRNA targets are cancer-associated. Further analysis revealed that GAS5, DLEU2, and nuclear paraspeckle assembly transcript 1 (NEAT1) were previously identified in lymphoma. In addition, MIR17HG, MIR155HG, MALAT1, and AFAP1-AS1 were the potential targets of KSHV-encoded miR-K12-11 (Sethuraman et al., 2018). Thirty-five cancer-relevant

**TABLE 1 | Cellular IncRNAs regulated by EBV and KSHV.**

| Viral genes | LncRNAs | Functions | References |
|-------------|---------|-----------|------------|
| EBV miR-BART14 | AFGL31P | Mitochondrial fusion; apoptosis | Li C.W. et al., 2018 |
| EBV miR-BART6-3p | LOC553103 | EMT; migration and invasion | He et al., 2016; Wang et al., 2020 |
| EBV | 7SL, H19, H19 antisense, p53 mRNA | Cell cycle; EBV tumorigenesis | Gallo et al., 2017 |
| EBV BHLLF1, LF3, BHRF1, BNLFL2a | SNHG8 | Cell cycle; DNA repair; EMT and ribosomal function; cell proliferation and colony formation | Huang et al., 2016; Lin et al., 2018; Naseem et al., 2018 |
| KSHV miR-K12-11 | MIR17HG, MIR155HG, AFAP1-AS1 | TGF-β signaling | Sethuraman et al., 2018 |
| KSHV miR-K12-9 | H19 | Tumor initiation; progression and metastasis | Sethuraman et al., 2018 |
| KSHV miR-K12-6-3p | UCA1 | Proliferation; migration | Sethuraman et al., 2018 |
| KSHV miR-K12-10b, 7 | TUG1 | Binding to PRG2 complexes | Sethuraman et al., 2018 |
| KSHV miR-K12-3, 4-3p, 8 | GAS5 | Tumor suppressor | He et al., 2017; Sethuraman et al., 2018 |
| KSHV miR-K12-4-3p, 7, 8, 9, 10a, 10b, 11, 12 EBV | MALAT1 | Proliferation and metastasis | Sethuraman et al., 2018; Chi et al., 2019 |
| KSHV miR-K12-4-3p | DLEU2 | Inducing apoptosis; histone modifications, DNA methylation | Sethuraman et al., 2018 |
| KSHV vIRF1 | Inc-OIP5P-AS1 | Proliferation, migration, and invasion | Li W. et al., 2019 |

**Notes:** BARTs, bamHI-A rightward transcripts; EBV, Epstein–Barr virus; EMT, epithelial–mesenchymal transition; KSHV, Kaposi’s sarcoma-associated herpesvirus; IncRNA, long non-coding RNA; MALAT1, metastasis-related lung adenocarcinoma transcript 1; TGF-β, transforming growth factor-β.
IncRNAs were identified, including the oncogenic IncRNAs MALAT1 and UCA1 and IncRNAs GAS5 and TUG1, which act as tumor suppressors (Sethuraman et al., 2018). Another study identified 126 IncRNAs including MEG3, ANRIL, and UCA1, which are closely implicated in cancer as putative targets of KSHV miRNA. They were found to reside in the nucleus and interact with miRNAs in endothelial cells (Sethuraman et al., 2017). Together, the IncRNAs that may interact with KSHV miRNAs in cancers are GAS5, MIR17HG, DLEU-2, MIR155HG, MALAT1, AFAP1-AS1, UCA1, TUG1, MEG3, ANRIL, and H19.

Several IncRNAs are abnormally expressed in KSHV-infected cells. LncRNA MIR17HG is the host gene of the miR-17-92 cluster, which is upregulated during KSHV infection, resulting in downregulation of transforming growth factor (TGF)-β signaling. UCA1 deregulation by KSHV increased the proliferation and migration of endothelial cells. Upregulation of UCA1 by TGF-β also promotes the development and progression of GC by augmenting GC cell proliferation and invasive and migratory capabilities (Zuo et al., 2017). MEG3 is downregulated in a variety of malignant tumors and acts as a tumor suppressor. LINC00313, which is upregulated by KSHV reactivation, was shown to interact with HIV Tat (Yang et al., 2020).

Kaposi’s sarcoma herpesvirus-encoded oncogene viral interferon regulatory factor 1 (vIRFI) hijacks the IncRNA OIP5 antisense RNA 1 (Inc-OIP5-AS1)/miR-218-5p axis to regulate the high-mobility group box 2 (HMGB2) and cytidine/uridine monophosphate kinase 1 (CMPK1) and promotes endothelial cell migration, invasion, and proliferation (Li W. et al., 2019). In addition, Inc-OIP5-AS1 increased DNA methylation of the pre-miR-218-1 promoter, inhibiting miR-218-5p expression. Inc-OIP5-AS1 also exerts its oncogenic functions and is consistently upregulated in GC cells (Rossetto and Pari, 2011).

Metastasis-related lung adenocarcinoma transcript 1 is a well-known IncRNA associated with several human cancers. It is closely related to tumor cell proliferation, angiogenesis, migration, invasion, and apoptosis and is regulated by various factors (Wang et al., 2014, 2018a; Lee et al., 2017; Du et al., 2018; Zhao et al., 2018; Duan et al., 2019). High expression of MALAT1 can be detected in the serum of GC patients, suggesting that MALAT1 is a potential biomarker for the diagnosis. MALAT1 can also be used as a therapeutic target of specific tumors (Hua et al., 2016). MALAT1 promotes cell proliferation and inhibits apoptosis of GC cells. By directly binding to SOX2 mRNA and enhancing the stability of SOX2 mRNA, MALAT1 can increase the stemness of GC cells (Xiao et al., 2019). Moreover, MALAT1 regulates the IL-21R signaling pathway in GC cells by competitively binding miR-125a. IL-21R has been identified as an oncogenic gene that promotes cell proliferation and invasion (Yan et al., 2019). Evidence suggests that the overexpression of MALAT1 increased cell proliferation, invasion, and migration in GC possibly through activation of the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway (Zhu et al., 2019). Specifically, MALAT1 overexpression promotes protein phosphorylation of PI3K, AKT, and signal transducer and activator of transcription 3 (STAT3) in GC cells (Dai et al., 2020). In addition, MALAT1 was demonstrated to competitively bind miR-181a-5p with AKT3, upregulating the AKT3 protein level to enhance cell growth (Lu et al., 2019). Furthermore, the MALAT1/miR-183/sirtuin 1 (SIRT1) axis was found to regulate cell apoptosis and autophagy via the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway in GC (Li H. et al., 2019). MALAT1 promotes chemotherapy resistance of GC cells by acting as a miRNA sponge. It also inhibits miR-30b expression by direct interaction and increases the expression of ATG5 by competitively binding miR-30b in GC, thereby potentiating autophagy-related cisplatin resistance (Xi et al., 2019); promotes GC cell oxaliplatin resistance via modulation of ZFP91 by sponging miR-22-3p (Zhang et al., 2020); promotes the invasion and metastasis of GC by regulating EGFL7 expression (Deng et al., 2016); and promotes GC tumorigenesis and progression via the MALAT1/miR-1297/HMGB2 axis or by facilitating vasculogenic mimicry (VM) and angiogenesis through multiple related signaling pathways (Li J. et al., 2017; Li Y. et al., 2017).

In NPC cells, MALAT1 promotes invasion and EMT via the de-repression of Capn4 by sponging miR-124 (Shi et al., 2017). The excessive expression of MALAT1 also downregulates E-cadherin, while upregulating N-cadherin and vimentin (Lee et al., 2017). Interestingly, MALAT1 can be influenced by miR-124 and miR-25 in NPC. For instance, TGF-β increases MALAT1 expression by repressing miRNA-124 (Du et al., 2018). MALAT1 is negatively regulated by miR-25 for Ago2-dependent degradation (Hua et al., 2016). These findings imply that MALAT1 may function crucially in all tumor processes induced by gammaherpesvirus. The functions of IncRNA MALAT1 in gastric cancer and NPC are summarized in Figure 2.

THE ROLES OF LONG NON-CODING RNAs IN EPSTEIN–BARR VIRUS-ASSOCIATED GASTRIC CARCINOMA

Gastric cancer is one of the most frequently occurring cancers worldwide. EBVaGC accounts for approximately 9% of the total number of GCs (Li et al., 2010; Iizasa et al., 2012; Nishikawa et al., 2014; Chen et al., 2015; Bae and Kim, 2016; Ribeiro et al., 2017; Castaneda et al., 2019; Qiao et al., 2019) and is one of the four major molecular subtypes (Cancer Genome Atlas Research Network, 2014). EBVaGC has a unique clinicopathological characteristic in that the frequency of lymph node metastasis is significantly lower (van Beek et al., 2004). However, the molecular mechanism of EBVaGC remains elusive (Tsao et al., 2017). Usually, EBV performs type I latency in EBVaGC, expressing EBNA1, EBERs, and BARts. LMP2A is expressed in approximately 50% of EBVaGC cases (Naseem et al., 2018). Therefore, miRNAs and IncRNAs play important regulatory roles in EBVaGC. Jing et al. (2018) established a complex regulatory network of transcription factors, IncRNAs, and EBV-related miRNAs in EBVaGC using multilevel expression data and a bioinformatics approach. They analyzed the gene expression profiling data sets (GSE51575) and built a transcription factor regulation network using Cytoscape. By
establishing the ceRNA network, they found that lncRNA RP5-1039K5.19 and TP73-AS1 may participate in the gene regulation of EBVaGC (Jing et al., 2018).

LONG NON-CODING RNAs IN EXOSOMES

Extracellular vesicles are mainly divided into apoptotic bodies, microvesicles, and exosomes. Exosomes are widely involved in material transportation and information transmission between cells. DNA, RNA, proteins, and other molecules are carried by exosomes and released from tumor cells, allowing the exchange of information and regulating tumor formation, growth, angiogenesis, metastasis, and drug resistance (Liu et al., 2017). In recent years, tumor-associated substances in exosomes have been a research hotspot, in particular, ncRNAs. New cancer-related diagnostics and prognostics based on ncRNA are developing rapidly. Recent studies have shown that IncRNAs can be secreted into peripheral blood by microvesicles and exosomes to affect cell–cell interactions (Liu et al., 2017; Xie et al., 2019). Thus, exosomal IncRNAs may become novel early diagnostic biomarkers for cancer progression. Herpesvirus-associated biomolecules can be shuttled from host cells to recipient cells to achieve an infection and even oncogenesis. Several studies have demonstrated the functions and roles of exosomes in the EBV tumorigenic process (Canitano et al., 2013; Aga et al., 2014; Teow et al., 2017). LncRNA ZFAS1 has been found to be elevated in serum exosomes of GC patients, indicating that it plays an active role in GC progression and represents a biomarker for GC diagnosis (Xie et al., 2019). However, no research has found that lncRNAs exist in KSHV-associated neoplasma-derived exosomes, whether they are of virus or cell origin (Zheng et al., 2019).

POTENTIAL LONG NON-CODING RNAs REGULATED BY EPSTEIN–BARR VIRUS AND KAPOSI’S SARCOMA HERPESVIRUS

**H19**

Long non-coding RNA H19, one of the best-known imprinted genes, has been widely proven to have carcinogenic effects (Matouk et al., 2007; Raveh et al., 2015). H19 is highly expressed and correlated with proliferation, invasion, and migration in most types of cancers and acts as a potential diagnostic and prognostic target (Figure 3; Zhang et al., 2014;
FIGURE 3: The function of long non-coding RNAs (lncRNAs) H19 and HOTAIR in gastric cancer and nasopharyngeal carcinoma. H19 (A) and HOTAIR (B) are involved in almost all tumor processes, and HOTAIR is more closely associated with tumor progression. They participate in the tumor processes through direct action, adsorption of microRNA (miRNA), or some currently unknown way to regulate gene expression.

Yoshimura et al., 2018; Ghafouri-Fard et al., 2020). H19 and miR-675 were upregulated in GC cells and tissues, promoting cell proliferation and inhibiting cell apoptosis. Further studies indicated that the H19/miR-675 axis inhibited the expression of Fas-associated protein with a novel death domain (FADD), subsequently inhibiting cleavage cascades of caspase 8 and caspase 3 (Yan et al., 2017). In another study, the expression of lncRNA H19 in GC was induced by c-Myc (Zhang et al., 2014). H19 knockdown studies verified that the pathway most affected by H19 is the EMT process (Zhang et al., 2017). H19 also plays a fundamental role in the regulation of autophagy through the induction of the PI3K/Akt/mTOR pathway in human cancers (Ghafouri-Fard et al., 2020). It has also been reported to have high levels of circulating H19 in GC patients, being inversely related to tumor size. However, the plasma level of H19 decreased significantly after tumor resection (Yörüker et al., 2018). Li X. et al. (2016) verified that H19 is involved in NPC metastasis by upregulating EZH2 expression via interaction with miR-630. The association between KSHV and H19 has been discussed above. Nonetheless, the role of H19 in EBV- and KSHV-induced tumors is an extensive subject.

Nuclear Paraspeckle Assembly Transcript 1

Nuclear paraspeckle assembly transcript 1 is highly expressed as an oncogenic gene in several types of solid tumors (Yu et al., 2017). Lu et al. (2016) reported that NEAT1 increased ZEB1 expression by targeting miR-204. Therefore, high levels of NEAT1 in NPC induce an EMT phenotype and are associated with a poor prognosis (Lu et al., 2016). Furthermore, NEAT1 was substantiated to directly interact with miR-124, promoting tumorigenesis and progression of NPC. NEAT1 upregulation promotes NPC tumorigenesis and progression by regulating the NF-κB signaling pathway (Cheng and Guo, 2017). In gastric cancer cells, upregulation of NEAT1 may promote cell proliferation, migration, and invasion via the miR-335-5p/ROCK1 axis (Wang et al., 2018b). NEAT1 was also found to be a target of KSHV miRNAs (Sethuraman et al., 2018).

HOTAIR

The lncRNA HOX transcript antisense intergenic RNA (HOTAIR), acknowledged as an oncogenic factor in various malignancies, is closely related to the regulation of EMT, including NPC and GC (Figure 3; Nie et al., 2013). HOTAIR mediates the invasion and metastasis of cancer cells via interaction with PRC2, which alters the methylation of H3K27 (Gupta et al., 2010). Its expression contributes to NPC tumorigenesis and progression by the upregulation of cyclooxygenase-2 (COX-2) via miR-101 sponging and fatty acid synthase (FASN) (Ma et al., 2017; Hu et al., 2018), and the expression is positively correlated with NPC poor prognosis. Besides, HOTAIR promotes angiogenesis in NPC by directly activating vascular endothelial growth factor A (VEGFA) or upregulating VEGFA and Ang2 expression through GRP78 (Fu et al., 2016).

HOX transcript antisense intergenic RNA can also promote the development of GC in various ways. Increased HOTAIR has been associated with lymph node metastasis and clinical stage and positively correlated with poor prognosis in GC patients (Da et al., 2017). This lncRNA participates in the development of GC by promoting GCP5 expression via sponging miR-217 (Dong et al., 2019). E-cadherin transcription was inhibited by HOTAIR through histone methylation at the E-cadherin promoter of HOTAIR in GC (Song et al., 2019). HOTAIR can also affect GC cell cycle distribution by regulating P21 and P53 proteins (Xu et al., 2019). HOTAIR could act as a ceRNA to repress miR-618 and subsequently increase KLF12 expression, inhibiting GC progression (Xun et al., 2019). By interacting with miR-34a, HOTAIR may also be involved in the PI3K/Akt and Wnt/β-catenin signaling pathways (Cheng et al., 2018). Thus,
REFERENCEs

Aga, M., Bentz, G. L., Raffa, S., Torrisi, M. R., Kondo, S., Wakisaka, N., et al. (2014). Exosomal HIF1alpha supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene. 33, 4613–4622. doi: 10.1038/onc.2014.66
genomic and functional features. *PLoS Pathog.* 10:e1003847. doi: 10.1371/journal.ppat.1003847

Bae, J. M., and Kim, E. H. (2016). Epstein-Barr virus and gastric cancer risk: a meta-analysis with meta-regression of case-control studies. *J. Prev. Med. Public Health* 49, 97–107. doi: 10.3961/jpmp.15.0668

Ballon, G., Chen, K., Perez, R., Tam, W., and Cesaran, E. (2011). Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. *J. Clin. Invest.* 121, 1141–1153. doi: 10.1172/jci44417

Borah, S., Darricarrere, N., Darnell, A., Myoung, J., and Steitz, J. A. (2011). A viral nuclear noncoding RNA binds re-localized poly(A) binding protein and is required for late KSHV gene expression. *PloS Pathog.* 7:e1002300. doi: 10.1371/journal.ppat.1002300

Bullard, W. L., Flemington, E. K., Renne, R., and Tibbetts, S. A. (2018). Connnivance, complicity, or collusion? The role of noncoding RNAs in promoting gammaherpesvirus tumorigenesis. *Trends Cancer* 4, 729–740. doi: 10.1016/j.trecan.2018.09.005

Campbell, M., and Izumiya, Y. (2020). PAN RNA: transcriptional exhaust from a viral engine. *J. Biomed. Sci.* 27, 41.

Campbell, M., Kim, K. Y., Chang, P. C., Huerta, S., Shevchenko, B., Wang, D. H., Campbell, M., and Izumiya, Y. (2020). PAN RNA: transcriptional exhaust from a viral engine. *J. Biomed. Sci.* 27, 41.

Canitano, A., Venturi, G., Borghi, M., Ammendolia, M. G., and Fais, S. (2013). EBV-encoded latent phase mRNAs. Exosomes released in vitro from Epstein-Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs.

Cheng, C., Qin, Y., Zhi, Q., Wang, J., and Qin, C. (2018). Knockdown of long non-coding RNA in cancer. *Cell Res.* 28, 1420–1434. doi: 10.1038/s41422-018-0172-7

Chi, Y., Wang, D., Wang, J., Yu, W., and Yang, J. (2019). Long non-coding RNA in cancer. *Cell Res.* 29, 17–28. doi: 10.1038/s41422-018-0172-7

Chen, Y., Wei, G., Xia, H., Tang, Q., and Bi, F. (2018). Long noncoding RNA ATB and epigenetic gene regulation of KSHV.

Da, M., Ma, J., Zhang, Y., Yang, J., Yao, J., Huang, B., et al. (2017). High expression level of long non-coding RNA HOTAIR is associated with poor overall survival in gastric cancer patients: evidence from meta-analysis. *J. BUON* 22, 911–918.

da Silva, S. R., and de Oliveira, D. E. (2011). HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. *Cancer Lett.* 305, 175–185. doi: 10.1016/j.canlet.2011.02.007

Dai, Q., Zhang, T., and Li, C. (2020). LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathway. *Cancer Manag. Res.* 12, 1939–1949. doi: 10.2147/cmrr.s43796

Deng, Q. J., Xie, L. Q., and Li, H. (2016). Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFl7 expression. *Life Sci.* 157, 38–44. doi: 10.1016/j.lfs.2016.05.041

Dong, X., He, X., Guan, A., Huang, W., Jia, H., Huang, Y., et al. (2019). Long non-coding RNA Hotair promotes gastric cancer progression via miR-217-GPC5 axis. *Life Sci.* 217, 271–282. doi: 10.1016/j.lfs.2018.12.024

Du, M., Chen, W., Zhang, W., Tian, X. K., Wang, T., Wu, J., et al. (2018). TGF-β regulates the ERK/MAPK pathway independent of the SMAD pathway by repressing miRNA-124 to increase MALAT1 expression in nasopharyngeal carcinoma. *Biomed. Pharmacother.* 99, 688–696. doi: 10.1016/j.biopha.2018.01.120

Duan, G., Zhang, C., Xu, C., Xu, C., Zhang, L., and Zhang, Y. (2019). Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the mi334a/cyclin D1 axis. *Int. J. Oncol.* 54, 17–28.

Frappier, L. (2015). EBNA1. *Curr. Top. Microbiol. Immunol.* 391, 3–34. doi: 10.1007/10.1128/jvi.03251-13

Gallo, A., Vella, S., Miele, M., Timoneri, F., Di Bella, M., Bosi, S., et al. (2017). Global profiling of viral and cellular non-coding RNAs in Epstein-Barr virus-induced lymphoblastoid cell lines and released exosome cargos. *Cancer Lett.* 388, 334–343. doi: 10.1016/j.canlet.2016.12.003

Ganem, D. (2010). KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. *J. Clin. Invest.* 120, 939–949. doi: 10.1172/jci40567

Ghafouri-Fard, S., Esmaeili, M., and Taheri, M. (2020). H19 lncRNA: roles in human biology and medicine. *J. Clin. Invest.* 120, 939–949. doi: 10.1172/jci40567

Grassmann, R., Fleckenstein, B., and Pfister, H. (2008). “Tumor viruses: human,” in *Encyclopedia of Virology*, 3 Edn, eds B. W. J. Mahy and M. H. V. Regenmortel (Amsterdam: Elsevier), 193–199.

Guo, J., Ma, J., Zhao, G., Li, G., Fu, Y., Luo, Y., et al. (2017). Long non-coding RNA LINC00868 functions as a tumor suppressor in nasopharyngeal carcinoma by targeting miR-214. *Onco. Res.* 25, 1189–1197. doi: 10.3727/10.1037/s0897-7177

He, B., Li, W., Wu, Y., Wei, F., Gong, Z., Bo, H., et al. (2016). Epstein-Barr virus-encoded miR-BART-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC255310. *Cell Death Dis.* 7, e2353. doi: 10.1038/cddis.2016.253

He, B., Zeng, J., Chao, W., Chen, X., Huang, Y., Deng, K., et al. (2017). Serum long non-coding RNAs MALAT1, AIFAP1-A51 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. *Oncotarget* 8, 41166–41177. doi: 10.18632/oncotarget.7050

He, M., Zhang, W., Bakken, T., Schutten, M., Toth, Z., Jung, J. L., et al. (2012). Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. *Cancer Res.* 72, 3582–3592. doi: 10.1158/0008-5472.can-11-2876

Holoch, D., and Moazed, D. (2015). RNA-mediated epigenetic regulation of gene expression. *Nat. Rev. Genet.* 16, 71–84. doi: 10.1038/nrg3863

Hu, W., Xu, W., Shi, Y., and Dai, W. (2018). LncRNA HOTAIR upregulates COX2 expression to promote invasion and migration of nasopharyngeal carcinoma by interacting with miR-101. *Biochem. Biophys. Res. Commun.* 505, 1090–1096. doi: 10.1016/j.bbrc.2018.09.190

Hua, W. F., Zhong, Q., Xia, T. L., Chen, Q., Zhang, M. Y., Zhou, A. J., et al. (2016). RBM24 suppresses cancers progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma. *Cell Death Dis.* 7, e2352. doi: 10.1038/cddis.2016.252
Huang, C., Wu, M., Tang, Y., Li, X., Ouyang, J., Xiao, L., et al. (2009). NAG7 promotes human nasopharyngeal carcinoma invasion through inhibition of estrogen receptor alpha and up-regulation of NK2AP1/MPM1 pathways. J. Cell Physiol. 221, 394–401. doi: 10.1002/jcp.21867

Huang, T., Ji, Y., Hu, D., Chen, B., Zhang, H., Li, C., et al. (2016). SNHG8 is identified as a key regulator of Epstein-barr virus(EBV)-associated gastric cancer by an integrative analysis of IncRNA and mRNA expression. Oncotarget 7, 80990–81002. doi: 10.18632/oncotarget.13167

Huarte, M. (2015). The emerging role of IncRNAs in cancer. Nat. Med. 21, 1253–1261. doi: 10.1038/nm.3981

Huarte, M., and Rinn, J. L. (2010). Large non-coding RNAs: missing in action? Hum. Mol. Genet. 19, R152–R161.

Hussein, H. A. M., Alfhili, M. A., Pakala, P., Simon, S., Hussain, J., McCubrey, J. A., et al. (2019). miRNAs and their roles in KSHV pathogenesis. Virus Res. 266, 15–24. doi: 10.1016/j.virusres.2019.03.024

Iizasa, H., Nanbo, A., Nishikawa, J., Jinushi, M., and Yoshiyama, H. (2012). In vitro cytotoxicity analysis of differential expressions of long non-coding RNAs in nasopharyngeal carcinoma. Biochem. Biophys. Res. Commun. 415, 394–399. doi: 10.1016/j.bbrc.2012.08.063

Ji, Y., Ji, Y., Hu, D., Chen, B., Zhang, H., Li, C., et al. (2016). SNHG8 inhibits cell growth in Epstein-Barr virus-associated gastric carcinoma. Cancer Lett. 353, 349–356. doi: 10.1016/j.canlet.2015.03.007

Kim, K. H., and Roberts, C. W. M. (2016). Targeting EZH2 in cancer. Nat. Med. 22, 128–134. doi: 10.1038/nm.4036

Krump, N. A., and You, J. (2018). Molecular mechanisms of viral oncogenesis in humans. Nat. Rev. Microbiol. 16, 684–698. doi: 10.1038/s41579-018-0064-6

Kung, J. T., Colognori, D., and Lee, J. T. (2013). Long noncoding RNAs: past, present, and future. Genetics 193, 651–669. doi: 10.1534/genetics.112.146704

Lin, Y., and Liu, X. (2019). LncRNA SNHG1 functions as a ceRNA to antagonize the effect of miR-145a-5p on the down-regulation of NUAK1 in nasopharyngeal cancer. Mol. Cancer Res. 17, 53–62. doi: 10.1158/1541-7786.MCR-17-0493

Lin, Y. H. (2020). Crosstalk of lncRNA and cellular metabolism and their regulatory mechanisms in cancer. Int. J. Mol. Sci. 21, 2947. doi: 10.3390/ijms21072947

Liu, J., Yang, C., Gu, Y., Li, C., Zhang, H., Zhang, W., et al. (2018). Knockdown of the IncRNA SNHG8 inhibits cell growth in Epstein-Barr virus-associated gastric carcinoma. Cell Mol. Biol. Lett. 23, 17.

Liu, J., Zhang, Y., Liu, W., Zhang, Q., Xiao, H., Song, H., et al. (2020). MiR-BART1-5p targets core 2beta-1,6-acetylgalactosaminyltransferase GCNT3 to inhibit cell proliferation and migration in EBV-associated gastric cancer. Virology 541, 63–74. doi: 10.1016/j.viro.2019.12.004

Liu, L., Zhou, Q., Xie, Y., Zuo, L., Zhu, F., and Lu, J. (2017). Extracellular vesicles: novel vehicles in herpesvirus infection. Virology Sin. 32, 349–356. doi: 10.1007/s12250-017-0473-9

Liu, W., and Ding, C. (2017). Roles of LncRNAs in viral infections. Front. Cell. Infect. Microbiol. 7:205. doi: 10.3389/fcimb.2017.00205

Lu, Y., Li, T., Wei, G., Liu, L., Chen, Q., Xu, L., et al. (2016). The long non-coding RNA NEAT1 regulates epithelial to mesenchymal transition and radioresistance in through miR-204/ZEβ1 axis in nasopharyngeal carcinoma. Tumour Biol. 37, 11733–11741. doi: 10.1007/s13277-015-4773-4

Lu, Z., Luo, T., Pang, T., Du, Z., Yin, X., Cui, H., et al. (2019). MALAT1 promotes gastric adenocarcinoma through the MALAT1/miR-181a-5p/akt3 axis. Open Biol. 9, 190095. doi: 10.1098/rsob.190095

Lung, R. W., Tong, J. H., Sung, Y. M., Leung, P. S., Ng, D. C., Chau, S. L., et al. (2009). Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 11, 1174–1184. doi: 10.1593/neo.098888

Ma, D. D., Yuan, L. L., and Lin, L. Q. (2017). LncRNA HOTAIR contributes to the tumorigenesis of nasopharyngeal carcinoma via up-regulating FASN. Eur. Rev. Med. Pharmacol. Sci. 21, 5143–5152.

Mansouri, S., Pan, Q., Blencowe, B. J., Claycomb, J. M., and Frappier, L. (2014). Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. J. Virol. 88, 11166–11177. doi: 10.1128/jvi.01785-14

Marquita, A. R., Mathur, A., Edwards, R. H., and Raab-Traub, N. (2015). Host gene expression is regulated by two types of noncoding RNAs transcribed from the Epstein-Barr Virus BamHI A rightward transcript region. J. Virol. 89, 11256–11268. doi: 10.1128/jvi.01492-15

Matouk, I. J., DeGroot, N., Mezan, S., Ayesh, S., Abu-Ial, R., Hochberg, A., et al. (2007). The H19 non-coding RNA is essential for human tumor growth. PloS One 2:e845. doi: 10.1371/journal.pone.0000845

Nasem, M., Barzi, A., Brezen-Masley, C., Puccini, A., Berger, M. D., Tokunaga, K., et al. (2018). Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 66, 15–22.

Nie, Y., Xi, Q., Sun, S., Dong, W., and Gong, C. (2013). Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival. Cancer Sci. 104, 458–464. doi: 10.1111/cas.12092

Nishikawa, J., Yoshihama, H., Iizasa, H., Kanehiro, Y., Nakamura, M., Nishimura, J., et al. (2014). Epstein-Barr virus in gastric carcinoma. Cancers (Basel) 6, 2259–2274.

Qiao, Y. W., Zhao, X. Q., Liu, J., and Yang, W. J. (2019). Clinicopathological features of Epstein-Barr virus-associated gastric cancer: a systematic review and meta-analysis. J. BUON 24, 1092–1099.

Rahel, E., Matouk, I. J., Gilson, M., and Hochberg, A. (2015). The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory. Mol. Cancer 14, 184.

Ribiero, J., Oliveira, A., Malta, M., Oliveira, C., Silva, F., Galghar, A., et al. (2017). Clinical and pathological characterization of Epstein-Barr virus-associated
LncRNAs in Gammaherpesvirus Infections

Shair, K. H., and Raab-Traub, N. (2012). Transcriptome changes induced by Epstein-Barr virus LMP1 and LMP2A in transgenic lymphocytes and by repressing the P15 and P16 expression.

Rossetto, C. C., and Pari, G. S. (2012). KSHV PAN RNA associates with demethylases UTX and JMD3 to activate lytic replication through a physical interaction with the virus genome. PLoS Pathog. 8:e1002680. doi: 10.1371/journal.ppat.1002680

Rossetto, C. C., and Pari, G. S. (2014). PAN’S Labyrinth: molecular biology of Kaposi’s sarcoma-associated herpesvirus (KSHV) PAN RNA, a multifunctional noncoding polyadenylated nuclear RNA. Viruses 6, 4212–4226. doi: 10.3390/v6114212

Sztuba-Solinska, J., Rausch, J. W., Smith, R., Miller, J. T., Whitby, D., and Le Grice, S. F. J. (2017). Kaposi’s sarcoma-associated herpesvirus polyadenylated nuclear RNA: a structural scaffold for nuclear, cytoplasmic and viral proteins. Nucleic Acids Res. 45, 6805–6821. doi: 10.1093/nar/gkx241

Tan, C., Peng, C., Huang, Y. C., Zhang, Q. H., Tang, K., Li, X. L., et al. (2002). Effects of NPC-associated gene NAG7 on cell cycle and apoptosis in nasopharyngeal carcinoma cells. Ai Zhong 21, 449–455.

Trowo, S. Y., Li, K., Khoo, A. S., and Peh, S. C. (2017). Pathogenic role of exosomes in Epstein-Barr Virus (EBV)-associated cancers. Int. J. Biol. Sci. 31, 1276–1286. doi: 10.7150/ijbs.19531

Tsao, S. W., Tsang, C. M., and Lo, K. W. (2017). Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos. Trans. R. Soc. Lond. B Biol. Sci. 372, 20160270.

Ungerleider, N., Concha, M., Lin, Z., Roberts, C., Wang, X., Cao, S., et al. (2018). The Epstein Barr virus circRNAome. PLoS Pathog. 14:e1007206. doi: 10.1371/journal.ppat.1007206

Ungerleider, N. A., Tibbetts, S. A., Renne, R., and Flemington, E. K. (2019). Gammaherpesvirus RNAs come full circle. mBio 10, e00071-19. doi: 10.1128/mBio.00071-19

van Beek, J., zur Hausen, A., Klein Kranenberg, E., van de Velde, C. J., Middeldorp, J. M., van den Brule, A. J., et al. (2004). EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J. Clin. Oncol. 22, 664–670. doi: 10.1200/jco.2004.08.061

Verhoeven, R. J., Tong, S., Zhang, G., Zong, J., Chen, Y., Jin, D. Y., et al. (2016). NF-kappaB signaling regulates expression of Epstein-Barr virus BART microRNAs and long noncoding RNAs in nasopharyngeal carcinoma. J. Virol. 90, 6475–6488. doi: 10.1128/jvi.00613-16

Verhoeven, R. J. A., Tong, S., Mok, B. W., Liu, J., He, S., Zong, J., et al. (2019). Epstein-Barr Virus BART long non-coding RNAs function as epigenetic modulators in nasopharyngeal carcinoma. Front. Oncol. 9:1120. doi: 10.3389/ fonc.2019.01120

Wang, D., Zeng, Z., Zhang, S., Xiong, F., He, B., Wu, Y., et al. (2020). Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell proliferation through the LOCC35103-STMN1 axis. FASEBJ 34, 8012–8027. doi: 10.1096/fj.202000099r

Wang, H., Wang, L., Zhang, G., Lu, C., Chu, H., Yang, R., et al. (2018a). MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. Oncotarget 9, 7501–7512. doi: 10.18632/oncotarget.23483

Wang, H., Zhang, M., and Sun, G. (2018b). Long non-coding RNA NEAT1 regulates the proliferation, migration and invasion of gastric cancer cells via targeting miR-335-5p/ROCK1 axis. Pharmazie 73, 150–155.

Wang, J., Su, L., Chen, X., Li, P., Cai, Q., Yu, B., et al. (2014). MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF. Biomed. Pharmacother. 68, 557–564. doi: 10.1016/j.biopha.2014.04.007

Wang, L. W., Jiang, S., and Gewurz, B. E. (2017). Epstein-Barr Virus LMP1-mediated oncogenicity. J. Virol. 91, e1718–e1716. doi: 10.1128/jvi.01718-17

Wang, M. W., Liu, J., Liu, Q., Xu, Q., Li, T. F., Jin, S., et al. (2017). LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of gastric cancer cells by repressing the P15 and P16 expression. Eur. Rev. Med. Pharmacol. Sci. 21, 4613–4622.

Wei, F., Gan, J., Wang, C., Zha, C., and Cai, Q. (2016). Cell cycle regulatory functions of the KSHV Oncoprotein LANA. Front. Microbiol. 7:334. doi: 10.3389/fmicb.2016.00334

Wilusz, J. E., Sunwoo, H., and Spector, D. L. (2009). Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 23, 1494–1504. doi: 10.1101/gad.180909

Xu, Z., Si, J., and Nao, J. (2019). LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA30b/autophagy related gene 5 axis in gastric cancer. Int. J. Oncol. 54, 239–248.

Xiao, Y., Pan, J., Geng, Q., and Wang, G. (2019). LncRNA MALAT1 increases the stemness of gastric cancer cells via enhancing SOX2 mRNA stability. FEBS Open Bio 9, 1212–1222. doi: 10.1002/fob2.12456

Xie, Y., Deng, W., Zhang, S., Yue, W., Yang, L., Zhai, D., et al. (2019). The role of exosomal noncoding RNAs in cancer. Mol. Cancer. 18, 37.

Xu, Z., Chen, Y., Yang, B., Liu, X., Zhou, X., and Kong, H. (2019). The association of HOTAIR with the diagnosis and prognosis of gastric cancer and its effect on the proliferation of gastric cancer cells. Can. J. Gastroenterol. Hepatol. 2019, 3076345.

Xun, J., Wang, C., Yao, J., Gao, B., and Zhang, L. (2019). Long non-coding RNA HOTAIR modulates KLF12 to regulate gastric cancer progression via
Zhang, E. B., Han, L., Yin, D. D., Kong, R., De, W., and Chen, J. (2014). c-Myc-Yang, W. S., Lin, T. Y., Chang, L., Yeh, W. W., Huang, S. C., Chen, T. Y., et al. Zhang, D. M., Lin, Z. Y., Yang, Z. H., Wang, Y. Y., Wan, D., Zhong, J. L., et al. Yu, X., Li, Z., Zheng, H., Chan, M. T., and Wu, W. K. (2017). NEAT1: a novel oncogenic role of Epstein-Barr virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma. J. Cell Mol. Med. 22, 38–45. doi: 10.1111/jcmm.13354

Zheng, Y., Zhang, W., Liu, W., Liu, H., Zhang, Y., and Luo, B. (2018). Epstein-Barr virus miRNA-BART16 modulates cell proliferation by targeting LMP1. Virus Res. 256, 38–44. doi: 10.1016/j.virusres.2018.08.001

Zhao, M., Wang, S., Li, Q., Ji, Q., Guo, P., and Liu, X. (2018). MALAT1: a long non-coding RNA highly associated with human cancers. Oncol. Lett. 16, 19–26.

Zheng, J., Shi, Y., Feng, Z., Zheng, Y., Li, Z., Zhao, Y., et al. (2019). Oncogenic effects of exosomes in gamma-herpesvirus-associated neoplasms. J. Cell Physiol. 234, 19167–19179. doi: 10.1002/jcp.28573

Zheng, Z. M. (2010). Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. Int. J. Biol. Sci. 6, 730–755. doi: 10.7150/ijs.6.730

Zhong, W., Wang, H., Herndier, B., and Ganem, D. (1996). Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc. Natl. Acad. Sci. U.S.A. 93, 6641–6646. doi: 10.1073/pnas.93.13.6641

Zhou, Y., Tian, B., Tang, J., Wu, J., Wang, H., Wu, Z., et al. (2020). SNHG7: a novel viral oncogenic IncRNA in human cancers. Biomed. Pharmacother. 124, 109921. doi: 10.1016/j.biotph.2020.109921

Zhu, K., Ren, Q., and Zhao, Y. (2019). IncRNA MALAT1 overexpression promotes proliferation, migration and invasion of gastric cancer by activating the PI3K/AKT pathway. Oncol. Lett. 17, 5335–5342.

Zuo, Z. K., Gong, Y., Chen, X. H., Ye, F., Yin, Z. M., Gong, Q. N., et al. (2017). TGFbeta1-induced IncRNA UCA1 upregulation promotes gastric cancer invasion and migration. DNA Cell Biol. 36, 159–167. doi: 10.1089/dna.2016.3553

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Liu, Zhang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.